ANDA 78616, held by Strides Pharma Intl. Zolpidem Tartrate.
As of Nov 16, 2026, ANDA 78616 (Zolpidem Tartrate), held by Strides Pharma Intl, was first approved by FDA on Nov 21, 2008, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 21, 2008 | Original application | Approved | None posted |
| Zolpidem Tartrate5MG · tablet;oral | Zolpidem Tartrate | Discontinued |
| Zolpidem Tartrate10MG · tablet;oral | Zolpidem Tartrate | Discontinued |
| Sep 2, 2022 | Supplement 17Labeling · Standard review | Approved | None posted |
| Aug 25, 2020 | Supplement 12Labeling · Standard review | Approved | None posted |
| Aug 25, 2020 | Supplement 13Labeling · Standard review | Approved | None posted |
| Aug 25, 2020 | Supplement 16Labeling · Standard review | Approved | None posted |
| Apr 2, 2015 | Supplement 9Labeling · Standard review | Approved | None posted |
| Sep 4, 2013 | Supplement 7Labeling · Standard review | Approved | None posted |
| Aug 16, 2010 | Supplement 2Labeling | Approved | None posted |
| Nov 21, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters